Biogen Acquires Apellis Pharmaceuticals
March 31, 2026
Biogen entered into a definitive agreement to acquire Apellis Pharmaceuticals in a ~$5.6 billion cash deal ($41 per share) that also includes contingent value rights (CVRs) tied to SYFOVRE sales performance. The transaction closed in May 2026 and made Apellis a wholly owned subsidiary of Biogen, adding commercial products EMPAVELI and SYFOVRE to Biogen’s immunology/rare disease portfolio and strengthening its expansion into nephrology.
- Buyers
- Biogen Inc.
- Targets
- Apellis Pharmaceuticals, Inc.
- Industry
- Healthcare Services
- Location
- Massachusetts, United States
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.